foxo4-dri p53 senolytic peptide study human trial regulates endothelial cell senescence via the signaling pathway FOXO4-DRI 10mg vial Frontiers Figure 5 — FOXO4-DRI alleviates

If you enjoy your Harvard Health Online Basic Bundle membership you can continue at the discounted rate of just $4.99/month billed automatically each quarter or $48.00/year billed automatically each year

A phase 2 trial in subjects with T2D investigating 2 g twice daily over 14 days reveals statistically significant improved glycemic control compared to placebo, which correlates with a mean weight loss of -1.8% (150152)

Available online at: (Accessed June 30, 2025)

Browse all Peptides & Longevity education Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims